We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
How to Approach Abbott Stock Following Its Sharp YTD Decline?
Read MoreHide Full Article
Key Takeaways
Abbott shares are down 29.4% YTD, lagging its industry, sector and selected peers.
Abbott cited weaker respiratory testing demand, China uncertainty and higher costs as challenges.
Abbott expects 2026 sales growth of 6.5%-7.5% and adjusted EPS of $5.38-$5.58.
Abbott (ABT - Free Report) has struggled in the market this year despite a series of regulatory, clinical and business developments. Shares have declined 29.4% year to date, underperforming the industry’s 24.1% drop and the Medical sector’s 5.8% plunge, while the S&P 500 composite has gained 9.7%. ABT closed the last trading session at $88.41, roughly 36.4% below its 52-week high of $139.06 and only 8% above its 52-week low of $81.97.
The stock’s performance has also lagged some notable peers. Shares of Becton, Dickinson and Company (BDX - Free Report) , or BD, have declined 25.8% this year, while Labcorp (LH - Free Report) has risen 2%. Since separating its Biosciences and Diagnostic Solutions business and its combination with Waters, BD has sharpened its focus as a pure-play MedTech company, which appears to be gaining traction. Labcorp, too, continues to benefit from its ongoing momentum in key specialty testing areas and strengthens its position as a top partner for health systems and regional local laboratories.
Image Source: Zacks Investment Research
From a technical standpoint, ABT is currently trading below its 50-day and 200-day moving averages, suggesting that shares could remain under pressure.
Image Source: Zacks Investment Research
Illinois-based Abbott is a major player in the healthcare space with several growth drivers across its diversified portfolio. The Established Pharmaceuticals Division is a steady contributor to the revenue base, supported by branded generics positions in faster-growing geographies. Within the Nutrition segment, the company is working through a transition that is intended to restore a healthier balance between price and volume over time. Medical Devices continues to benefit from scale advantages and new product cycles across Cardiovascular and Diabetes units. Still, several challenges continue to weigh on the near-term outlook.
What’s Holding Back Abbott?
Respiratory Testing Demand Remains Volatile: Abbott’s Diagnostics results still face mixed swings as respiratory virus testing continues to normalize from prior years. In the first quarter of 2026, Rapid and Molecular Diagnostics declined 9.6% on a comparable basis, reflecting lower demand for respiratory virus tests versus the prior-year season. While Core Laboratory grew 3.3% on a comparable basis and Cancer Diagnostics added growth following the Exact Sciences acquisition, the segment’s near-term reported profile can remain uneven as respiratory seasons fluctuate and pandemic-related comparisons fade.
Macro-Driven Cost Pressures: Abbott continues to operate against an uncertain macroeconomic backdrop that can influence input costs and demand patterns across categories. In the first quarter of 2026, selling, general and administrative expenses increased 22.2% year over year, partly reflecting acquisition-related items, and the company continues to incur incremental costs tied to European MDR and IVDR compliance. If pricing, mix or volumes weaken in areas such as Nutrition, Abbott may have less flexibility to offset these costs, which could weigh on profitability even with ongoing cost actions.
China Policy Uncertainty Lingers:China remains a source of uncertainty, particularly within Diagnostics, where government procurement policies have affected pricing and volumes. Management indicated that Core Laboratory trends in China were flat in the first quarter of 2026 and expects China to remain down for the full year, even as the company laps parts of prior pricing actions. Future procurement rounds and policy shifts can still alter demand visibility and create additional volatility versus Abbott’s more stable geographies.
Abbott’s FY 2026 Guidance
With the Exact Sciences acquisition now complete, Abbott expects full-year 2026 sales growth outlook 6.5% to 7.5% on both a reported and comparable basis. The company also updated its adjusted earnings per share (EPS) guidance to $5.38-$5.58. The new midpoint of $5.48 reflects roughly $0.20 of dilution tied to the acquisition.
At present, the Zacks Consensus Estimate expects Abbott’s earnings to rise 6.4% in 2026 and another 10.5% in 2027. However, estimates have seen downward revisions over the past 90 days.
Image Source: Zacks Investment Research
The consensus mark for Abbott’s revenues calls for 13.9% and 8.9% growth in 2026 and 2027, respectively.
ABT’s Valuation Snapshot
With a Value Score of C, Abbott is currently trading at a forward, five-year, Price/Sales of 2.93X, representing a premium to the industry average of 2.05X.
Image Source: Zacks Investment Research
ABT also has a higher sales multiple compared to Labcorp’s 1.39X five-year P/S, as well as Becton, Dickinson’s P/S of 2.02X.
Conclusion
Abbott’s sharp year-to-date decline reflects the impact of a weaker-than-expected respiratory season on its quarterly results, dilution risk from the Exact Sciences acquisition and ongoing macroeconomic pressures, among others. In China, management continues to maintain a cautious outlook despite flat Core Laboratory trends in the first quarter. The company’s technical indicators also point to continued weakness. Analysts have revised Abbott’s fiscal-year 2026 and 2027 estimates lower in recent months. Given its elevated valuation relative to industry and peers, existing ABT holders may want to exit their positions until visibility into near-term performance improves.
View the Zacks #1 Rank List
Image: Bigstock
How to Approach Abbott Stock Following Its Sharp YTD Decline?
Key Takeaways
Abbott (ABT - Free Report) has struggled in the market this year despite a series of regulatory, clinical and business developments. Shares have declined 29.4% year to date, underperforming the industry’s 24.1% drop and the Medical sector’s 5.8% plunge, while the S&P 500 composite has gained 9.7%. ABT closed the last trading session at $88.41, roughly 36.4% below its 52-week high of $139.06 and only 8% above its 52-week low of $81.97.
The stock’s performance has also lagged some notable peers. Shares of Becton, Dickinson and Company (BDX - Free Report) , or BD, have declined 25.8% this year, while Labcorp (LH - Free Report) has risen 2%. Since separating its Biosciences and Diagnostic Solutions business and its combination with Waters, BD has sharpened its focus as a pure-play MedTech company, which appears to be gaining traction. Labcorp, too, continues to benefit from its ongoing momentum in key specialty testing areas and strengthens its position as a top partner for health systems and regional local laboratories.
Image Source: Zacks Investment Research
From a technical standpoint, ABT is currently trading below its 50-day and 200-day moving averages, suggesting that shares could remain under pressure.
Image Source: Zacks Investment Research
Illinois-based Abbott is a major player in the healthcare space with several growth drivers across its diversified portfolio. The Established Pharmaceuticals Division is a steady contributor to the revenue base, supported by branded generics positions in faster-growing geographies. Within the Nutrition segment, the company is working through a transition that is intended to restore a healthier balance between price and volume over time. Medical Devices continues to benefit from scale advantages and new product cycles across Cardiovascular and Diabetes units. Still, several challenges continue to weigh on the near-term outlook.
What’s Holding Back Abbott?
Respiratory Testing Demand Remains Volatile: Abbott’s Diagnostics results still face mixed swings as respiratory virus testing continues to normalize from prior years. In the first quarter of 2026, Rapid and Molecular Diagnostics declined 9.6% on a comparable basis, reflecting lower demand for respiratory virus tests versus the prior-year season. While Core Laboratory grew 3.3% on a comparable basis and Cancer Diagnostics added growth following the Exact Sciences acquisition, the segment’s near-term reported profile can remain uneven as respiratory seasons fluctuate and pandemic-related comparisons fade.
Macro-Driven Cost Pressures: Abbott continues to operate against an uncertain macroeconomic backdrop that can influence input costs and demand patterns across categories. In the first quarter of 2026, selling, general and administrative expenses increased 22.2% year over year, partly reflecting acquisition-related items, and the company continues to incur incremental costs tied to European MDR and IVDR compliance. If pricing, mix or volumes weaken in areas such as Nutrition, Abbott may have less flexibility to offset these costs, which could weigh on profitability even with ongoing cost actions.
China Policy Uncertainty Lingers:China remains a source of uncertainty, particularly within Diagnostics, where government procurement policies have affected pricing and volumes. Management indicated that Core Laboratory trends in China were flat in the first quarter of 2026 and expects China to remain down for the full year, even as the company laps parts of prior pricing actions. Future procurement rounds and policy shifts can still alter demand visibility and create additional volatility versus Abbott’s more stable geographies.
Abbott’s FY 2026 Guidance
With the Exact Sciences acquisition now complete, Abbott expects full-year 2026 sales growth outlook 6.5% to 7.5% on both a reported and comparable basis. The company also updated its adjusted earnings per share (EPS) guidance to $5.38-$5.58. The new midpoint of $5.48 reflects roughly $0.20 of dilution tied to the acquisition.
At present, the Zacks Consensus Estimate expects Abbott’s earnings to rise 6.4% in 2026 and another 10.5% in 2027. However, estimates have seen downward revisions over the past 90 days.
Image Source: Zacks Investment Research
The consensus mark for Abbott’s revenues calls for 13.9% and 8.9% growth in 2026 and 2027, respectively.
ABT’s Valuation Snapshot
With a Value Score of C, Abbott is currently trading at a forward, five-year, Price/Sales of 2.93X, representing a premium to the industry average of 2.05X.
Image Source: Zacks Investment Research
ABT also has a higher sales multiple compared to Labcorp’s 1.39X five-year P/S, as well as Becton, Dickinson’s P/S of 2.02X.
Conclusion
Abbott’s sharp year-to-date decline reflects the impact of a weaker-than-expected respiratory season on its quarterly results, dilution risk from the Exact Sciences acquisition and ongoing macroeconomic pressures, among others. In China, management continues to maintain a cautious outlook despite flat Core Laboratory trends in the first quarter. The company’s technical indicators also point to continued weakness. Analysts have revised Abbott’s fiscal-year 2026 and 2027 estimates lower in recent months. Given its elevated valuation relative to industry and peers, existing ABT holders may want to exit their positions until visibility into near-term performance improves.
Abbott currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.